<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA warns GLP-1 drugs carry potential risk of rare eye condition — Live Feed</title><link>https://www.live-feeds.com/feed/fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA adds rare vision-loss warning to GLP-1 drugs including Ozempic and Zepbound</title><link>https://www.live-feeds.com/feed/fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition#u203528</guid><pubDate>Mon, 16 Nov 2026 06:11:47 +0000</pubDate><description>The U.S. Food and Drug Administration has required class-wide label updates for GLP-1 receptor agonists to warn of a potential risk of nonarteritic anterior ischemic optic neuropathy, a rare eye condition that can cause sudden vision loss. Drugs affected include Ozempic, Wegovy, Mounjaro and Zepbound. One FDA study found an increased risk against DPP-4 inhibitors but not SGLT-2 inhibitors, while a trial review recorded 15 probable cases. Manufacturers must add the warning to prescribing information. The agency has not established a causal link between the drugs and the condition.Why it matters</description></item>
</channel></rss>